Geriatric and Surgical Comanagement for Older Patients With Cancer: Armin Shahrokni, MD, MPH

Patients aged 75 years and older face an increased risk of mortality and postoperative events when undergoing surgical treatment for cancer. In a study recently published in JAMA Network Open, a research team led by first author Armin Shahrokni, MD, MPH, found that patients whose care was managed by both the surgical and geriatric teams experienced significantly better outcomes compared with those whose care was provided by the surgical team alone. In this interview with i3 Health, Dr. Shahrokni...
Continue reading

Tafasitamab/Lenalidomide for Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Gilles Salles, MD, PhD

Recently, the FDA granted accelerated approval to tafasitamab-cxix (Monjuvi®, MorphoSys US Inc.) in combination with lenalidomide for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible for autologous stem cell transplantation. In this interview with i3 Health, Gilles Salles, MD, PhD, principal investigator of the phase 2 L-MIND trial, on which the approval was based, discusses the significance of the approval, adverse events of note with tafasitamab/lenal...
Continue reading

Geriatric Comanagement Improves Surgical Outcomes in Older Patients With Cancer

In older patients with cancer undergoing surgical treatment, collaboration between surgical and geriatric teams significantly decreases 90-day postoperative mortality. Patients aged 75 years and older face unique challenges when undergoing cancer-related surgery, including an increased risk of adverse postoperative events, a heightened risk of delirium, difficulties in recovering mobility and functional activity, and the need for appropriate care after hospital discharge. However, collaboration ...
Continue reading

Nivolumab/Ipilimumab Approved for Metastatic Non-Small Cell Lung Cancer

For patients with advanced non-small cell lung cancer (NSCLC) that test positive for programmed death-ligand 1 (PD-L1), the FDA just approved an effective treatment: nivolumab (Opdivo ®, Bristol Myers Squibb) plus ipilimumab (Yervoy®, Bristol Myers Squibb). A companion diagnostic, PD-L1 IHC 28.8 pharmDx (Agilent Technologies, Inc.), was also FDA approved for selecting patients with NSCLC for treatment with nivolumab/ipilimumab. Previously approved to treat advanced kidney cancer, advanced liver ...
Continue reading

Rucaparib Approved: BRCA-Mutated Metastatic CRPC

The FDA has granted accelerated approval to rucaparib (Rubraca®, Clovis Oncology, Inc.) for patients with deleterious germline and/or somatic BRCA-mutated metastatic castration-resistant prostate cancer (CRPC) who have previously received one line of taxane-based chemotherapy and one or more lines of androgen receptor-directed therapy. The approval was based on TRITON2 (NCT02952534), a phase 2 clinical trial which enrolled 115 patients with BRCA-mutated metastatic CRPC. Patients received 600 mg ...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.